Marginal zone B-cell lymphoma
Drug research and approvals for marginal zone B-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 95 studies of marginal zone B-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 95
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 0
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non…NCT07763210 · Phase 2 · Vanderbilt-Ingram Cancer Center · starts Sep 25, 2026
- A Study of ARC-02 in B-cell NHLNCT07691606 · Phase 1 · Taiho Oncology, Inc. · starts Jun 22, 2026
- Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment…NCT07583810 · Phase 2 · City of Hope Medical Center · starts Oct 23, 2026
- Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaNCT07554898 · Phase 2 · Zhejiang Cancer Hospital · starts Apr 16, 2026
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLNCT07448324 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Apr 1, 2025
- Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLNCT07441993 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Jan 5, 2026
- A Study of APG-3288 in Relapsed/Refractory Blood CancersNCT07424833 · Phase 1 · Ascentage Pharma Group Inc. · starts Mar 10, 2026
- Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.NCT07372365 · Phase 2 · The First Affiliated Hospital of Soochow University · starts Oct 24, 2025
Approved 1
- UmbralisibPI3-kinase p110-delta subunit inhibitor
Phase 3 11
- RituximabB-lymphocyte antigen CD20 binding agent
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- BendamustineDNA inhibitor
- ChlorambucilDNA inhibitor
- CyclophosphamideDNA inhibitor
- IbrutinibTyrosine-protein kinase BTK inhibitor
- OrelabrutinibTyrosine-protein kinase BTK inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- VincristineTubulin inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Dextrose
Phase 2 12 of 24
- Bortezomib26S proteasome inhibitor
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- Tositumomab 131IB-lymphocyte antigen CD20 binding agent
- CladribineDNA inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- Fludarabine
- MethotrexateDihydrofolate reductase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- MosunetuzumabT cell surface glycoprotein CD3 binding agent
- VorinostatHistone deacetylase 1 inhibitor
Phase 1 or earlier 10
- Yttrium y 90 ibritumomab tiuxetanB-lymphocyte antigen CD20 binding agent
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- TanespimycinHeat shock protein HSP90 inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- OprelvekinInterleukin 11 receptor alpha agonist
- DasatinibTyrosine-protein kinase ABL inhibitor
- AlvocidibCyclin-dependent kinase 2 inhibitor
- AgatolimodToll-like receptor 9 agonist
- IanalumabTumor necrosis factor receptor superfamily member 13C binding agent
- Indium in 111 ibritumomab tiuxetan
How its trials ended
321 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 108 whose ending is known, 41% met their primary endpoint, 1% missed it and 58% stopped early.
- Completed, result not reported10332%
- Ongoing9530%
- Met its primary endpoint4414%
- Stopped: other or unclear278%
- Stopped: enrollment or feasibility165%
- Status unknown155%
- Stopped: sponsor or business decision113%
- Stopped: lack of efficacy52%
- Stopped: funding31%
- Missed its primary endpoint1<1%
- Stopped: safety1<1%
| Dec 7, 2015 | BendekaTreatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with… | Eagle Pharmaceuticals, Inc. | Approved |
| Oct 31, 2008 | TreandaTreatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a… | Cephalon, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA